Complete resolution of lung metastasis confirmed at 4 month follow-up in hormone receptor positive (HR+) breast cancer ...

Zongertinib, an oral therapy shown to have strong responses in patients previously treated for HER2 -mutated non–small cell ...

BriaCell confirms complete resolution of lung metastasis at 4 months in Phase 1/2a trial using Bria-OTS immunotherapy in advanced breast cancer.

Therapeutics confirms the sustained complete resolution of the lung metastasis, first reported in February 2025, two months ...

The FDA has completed its 30-day review of an application for Hepzato in combination with standard of care in liver-dominant ...

It had been hoped that RA patients might actually benefit more from these drugs, known as immune checkpoint inhibitors (ICIs) ...

How one man, along with his care team, turned an all-consuming cancer diagnosis into a management strategy with inspiration ...

Zongertinib shows promise for treating HER2-mutant non–small cell lung cancer (NSCLC), with significant activity against brain metastases and low interstitial lung disease risk, explains John Heymach, ...

Bria-OTS is currently being investigated as a personalized off-the-shelf immunotherapy in a Phase 1/2a dose escalation study for metastatic recurrent breast cancer. The study will evaluate the safety ...

The HER2-targeted therapy zongertinib demonstrated clinical benefits for previously treated patients with advanced ...

Boehringer Ingelheim’s drug candidate for human epidermal growth factor receptor 2 (HER2)-mutated non-small cell lung cancer ...